academic

Sun Yat-sen University

Account opportunity

Not established

Relationship

Active signals

Trials as sponsor

Why this account matters

Sun Yat-sen University

New trial — Garsorasib In KRAS G12C Mutant Locally Advanced and Metastatic NSCLC

New trialNCT07294261

53/100

Opportunity

Commercial fit11/25

Clinical timing20/20

Biomarker need5/20

Relationship2/10

Signal strength9/10

Account value5/10

Urgency1/5

New phase 2 trial NCT07294261 posted by Sun Yat-sen University: "Garsorasib In KRAS G12C Mutant Locally Advanced and Metastatic NSCLC". New trial on a phase 2 not yet recruiting study is a moment when external vendors are commonly selected or expanded (spec §70).

Why nowClinicalTrials.gov record updated 263 days ago.

ConfidenceHigh · 87%clinical development · translational medicine · clinical operations

Draft outreach Review

NextHold. Score is below the tenant threshold (55). Keep on the watchlist for follow-on signals.

Sun Yat-sen University

New trial — TCR-T Cell Therapy for KRAS Mutation in Advanced Solid Tumors

New trialNCT07342738

52/100

Opportunity

Commercial fit11/25

Clinical timing19/20

Biomarker need5/20

Relationship2/10

Signal strength9/10

Account value5/10

Urgency1/5

New early phase_1 trial NCT07342738 posted by Sun Yat-sen University: "TCR-T Cell Therapy for KRAS Mutation in Advanced Solid Tumors". New trial on a early phase_1 not yet recruiting study is a moment when external vendors are commonly selected or expanded (spec §70).

Why nowClinicalTrials.gov record updated 236 days ago.

ConfidenceHigh · 87%clinical development · translational medicine · clinical operations

Draft outreach Review

NextHold. Score is below the tenant threshold (55). Keep on the watchlist for follow-on signals.

Trials

Trial	Phase	Testing language
NCT07342738 TCR-T Cell Therapy for KRAS Mutation in Advanced Solid Tumors	early phase 1	mol. elig.
NCT07294261 Garsorasib In KRAS G12C Mutant Locally Advanced and Metastatic NSCLC	phase 2	mol. elig.